WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009065121) INCREASED STABILITY OF A DNA FORMULATION BY INCLUDING POLY-L-GLUTAMATE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/065121    International Application No.:    PCT/US2008/083785
Publication Date: 22.05.2009 International Filing Date: 17.11.2008
Chapter 2 Demand Filed:    16.09.2009    
IPC:
A61K 48/00 (2006.01), A61K 39/00 (2006.01), C12N 15/63 (2006.01)
Applicants: VGX PHARMACEUTICALS, INC. [US/US]; 450 Sentry Parkway Blue Bell, PA 19422 (US) (For All Designated States Except US).
DRAGHIA-AKLI, Ruxandra [FR/US]; (US) (For US Only).
POPE, Melissa [US/US]; (US) (For US Only)
Inventors: DRAGHIA-AKLI, Ruxandra; (US).
POPE, Melissa; (US)
Agent: KIM, Thomas, S.; VGX Pharmaceuticals 450 Sentry Parkway Blue Bell, PA 19422 (US)
Priority Data:
11/941,921 16.11.2007 US
10/156,670 28.05.2002 US (IA Considered Withdrawn 26.01.2009)
10/395,709 24.03.2003 US (IA Considered Withdrawn 26.01.2009)
Title (EN) INCREASED STABILITY OF A DNA FORMULATION BY INCLUDING POLY-L-GLUTAMATE
(FR) FORMULATION D'ADN PRÉSENTANT UNE STABILITÉ ACCRUE GRÂCE À L'INCORPORATION DE POLY-L-GLUTAMATE
Abstract: front page image
(EN)Aspects of the present invention is related to DNA vaccine formulations having enhanced stability comprising at least one DNA plasmid capable of expressing an antigen in cells of mammal and poly-L-glutamate; wherein the DNA plasmid is present in the vaccine formulation at a concentration of at least 1 mg/ml, and the poly-L-glutamate is present in the amount of weight that is 1 % of the amount of DNA plasmid. Some aspects of the present invention is related to methods of stabilizing DNA plasmid in a DNA vaccine formulation. Additionally, the present invention is related to methods for introducing a DNA vaccine formulation having enhanced stability into a cell of a selected tissue in a recipient.
(FR)Des aspects de l'invention concernent des formulations de vaccins ADN présentant une stabilité accrue qui comprennent au moins plasmide d'ADN pouvant exprimer un antigène dans des cellules de mammifère et du poly-L-glutamate. Le plasmide d'ADN est présent dans la formulation de vaccin à une concentration d'au moins 1 mg/ml, et le poly-L-glutamate est présent dans une quantité de poids égale à 1 % de la quantité de plasmide d'ADN. Certains aspects de l'invention concernent des procédés permettant de stabiliser le plasmide d'ADN d'une formulation de vaccin ADN. En outre, l'invention concerne des procédés permettant d'introduire, chez un receveur, une formulation de vaccin ADN à stabilité accrue dans une cellule de tissu sélectionné.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)